BioHall Consultoria, Pesquisa e Inovação, Itajai, Santa Catarina, Brazil.
Gabbia Biotechnology, Itajai, Santa Catarina, Brazil.
Int J Cosmet Sci. 2023 Oct;45(5):572-580. doi: 10.1111/ics.12850. Epub 2023 Jun 20.
The microbiome plays an important role in a wide variety of skin disorders. Hence, dysbiosis in the skin and/or gut microbiome is associated with an altered immune response, promoting the development of skin diseases, such as atopic dermatitis, psoriasis, acne vulgaris and dandruff. Studies have shown that paraprobiotics may be promising for the treatment of skin disorders through microbiota modulation and immunomodulation. So, the objective is to develop an anti-dandruff formulation using a paraprobiotic (Neoimuno) as active ingredient.
Randomized, double-blind, placebo-controlled clinical trial was performed in patients who had any degree of dandruff. A total of 33 volunteers were recruited and randomly divided into two groups: placebo or treated. (1% Neoimuno). The ingredient used was Neoimuno (Bifidobacterium lactis strain CCT 7858). Combability analysis and perception questionnaire were applied before and after treatment. Statistical analyses were performed.
No adverse effects were reported by patients throughout the study. Through the combability analysis, a significant decrease in the number of particles was verified after 28 days of shampoo use. Regarding perception, there was a significant difference for the cleaning variables and improvement of the general appearance 28 days after the intervention. There were no significant differences for the itching and scaling parameters, as well as the perception parameters at 14 days.
Topical application of the paraprobiotic shampoo containing 1% Neoimuno was able to significantly improve the feeling of cleanliness and general aspects of dandruff, in addition to reducing scalp flakiness. Thus, with the results obtained through the clinical trial, Neoimuno presents itself as a natural, safe and effective ingredient in the treatment of dandruff. The efficacy of Neoimuno in dandruff was visible within 4 weeks.
微生物组在多种皮肤疾病中发挥着重要作用。因此,皮肤和/或肠道微生物组的失调与免疫反应改变有关,促进了皮肤疾病的发展,如特应性皮炎、银屑病、寻常痤疮和头皮屑。研究表明,通过微生物组调节和免疫调节,拟益生菌可能是治疗皮肤疾病的有前途的方法。因此,目的是开发一种使用拟益生菌(Neoimuno)作为活性成分的抗头皮屑配方。
在有任何程度头皮屑的患者中进行了一项随机、双盲、安慰剂对照的临床试验。共招募了 33 名志愿者,并随机分为两组:安慰剂或治疗组(1% Neoimuno)。所用成分是 Neoimuno(双歧杆菌 CCT 7858 菌株)。在治疗前后进行了可梳理性分析和感知问卷。进行了统计分析。
在整个研究过程中,患者均未报告不良反应。通过可梳理性分析,在使用洗发水 28 天后,验证了颗粒数量的显著减少。关于感知,在干预后 28 天,清洁变量和整体外观改善方面存在显著差异。在干预后 14 天,瘙痒和鳞屑参数以及感知参数没有显著差异。
含有 1% Neoimuno 的拟益生菌洗发水的局部应用能够显著改善清洁感和头皮屑的整体外观,此外还能减少头皮鳞屑。因此,通过临床试验获得的结果表明,Neoimuno 是一种天然、安全、有效的治疗头皮屑的成分。Neoimuno 在头皮屑中的疗效在 4 周内可见。